Skip to content
About
Company Overview
Our Investors
Our Team
Our Approach
Treg Platform
Off-the-shelf Allo
Scalable Manufacturing
Pipeline & Programs
Our Pipeline
GNTI-122 – T1D (POLARIS)
GNTI-148 – T1D
GNTI-932 – IBD
GNTI-350 – B/T cell-driven AID
GNTI-823 – Acute Inflammatory
News
Genti in the News
Publications
Conference Presentations
Contact
Locations
Careers
Toggle navigation
About
Company Overview
Our Investors
Our Team
Our Approach
Treg Platform
Off-the-shelf Allo
Scalable Manufacturing
Pipeline & Programs
Our Pipeline
GNTI-122 – T1D (POLARIS)
GNTI-148 – T1D
GNTI-932 – IBD
GNTI-350 – B/T cell-driven AID
GNTI-823 – Acute Inflammatory
News
Genti in the News
Publications
Conference Presentations
Contact
Locations
Careers
Genti Publication
October 02, 2025
iPSC Summit Hypo-Immune Allogeneic EngTregs show long-term persistence
Click here to download PDF
‹ Back to Publications
Toggle navigation
Toggle navigation